These are defined as follows in Unitaid’s Strategy 2017-2021:
Innovation and availability: There is a robust pipeline of new products, regimens or formulations intended to improve clinical efficacy, reduce cost, or better meet the needs of end users, providers or supply chain managers. It means that new and/or superior, evidence-supported, adapted products are commercially available and ready for rapid introduction in low income countries and lower-middle income countries.
Quality: The medicine or technology is quality-assured, and there is reliable information on the quality of the product.
Affordability: The medicine or technology is offered at the lowest sustainable price and does not impose an unreasonable financial burden on governments, donors, individuals, or other payers, with a view to increasing access for the underserved.
Demand and adoption: Countries, programs, providers (e.g., healthcare providers, retailers), and end users rapidly introduce and adopt the most cost-effective products within their local context.
Supply and delivery: Supply chain systems, including quantification, procurement, storage, and distribution, function effectively to ensure that products reach end users in a reliable and timely way. Adequate and sustainable supply exists to meet global needs.